Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

smart watch

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Purdue gets FDA nod for abuse-deterrent painkiller

Around 105 people per day die from a drug overdose in the US

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Sanofi reception

Sanofi plans 18 new product launches by 2020

Keen to reinstall faith of investors after firing CEO Viehbacher

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links